22-Apr-2014 - With Pfizer rumoured to be on the brink of a mega-merger with AstraZeneca, in-Pharmatechnologist.com brings you an interactive view of what £60bn ($101bn) could get.
17-Apr-2014 - Albemarle has agreed to sell its ibuprofen business to US chemical intermediates firm SI Group in a deal that will also see it divest the anaesthetic agent, propofol.
07-Apr-2014 - Regulatory compliance will be the number one focus for Sun Pharma, the company says, following its $3.2bn (€2.3bn) takeover of Indian generics firm Ranbaxy.
01-Apr-2014 - Lupin has bought Mexican eye drugmaker Grin in a deal that gives it a “bridgehead” to grow its API and generics business in the region.
18-Mar-2014 - The Board of Directors at Indian firm Orchid has approved the sale of its API business to Hospira, bringing the acquisition a step closer to completion.
17-Mar-2014 - Twin changes at AstraZeneca's MedImmune kick off this week's gallery, as well as jobs news from Europe
18-Feb-2014 - Actavis has confirmed it will acquire Forest Laboratories in a deal worth up to $25bn (€18bn) following rumours last night.
06-Feb-2014 - An increased trend in dealmaking for targeted drug delivery last year will continue to drive partnerships in 2014, according to a pharmaceutical partnering expert.
03-Feb-2014 - Lupin Ltd has bought Dutch delivery technology company Nanomi BV in a deal that moves the Indian generics firm into the complex injectables space.
23-Jan-2014 - Increased in-house API production and manufacturing in India will lower the costs of Hospira’s injectables, the firm says, as it looks past current remediation efforts.
16-Jan-2014 - Complex generics will represent over 50% of Teva’s generic market by 2017, the firm says, but investments in delivery technology will have positive implications across the full business.
13-Jan-2014 - Alnylam has both acquired Merck & Co. subsidiary Sirna therapeutics and extended an alliance with Genzyme in order to advance its small interfering RNA (siRNA) delivery programme.
07-Jan-2014 - Aerogen has licensed its respiratory drug delivery technology to Dutch electronics giant Philips in a deal announced today.
06-Jan-2014 - Chinese API firm Shenzhen Hepalink has announced plans to buy Scientific Protein Laboratories (SPL) from private equity investor American Capital for $337.5m.
18-Dec-2013 - Encap has collaborated with Lipocine to manufacture its oral testosterone product and says it expects continued growth in demand for HPAPI formulation services.
25-Nov-2013 - Pfizer says it intends to shutter a manufacturing facility in Puerto Rico just days after Merck & Co. announced it was reducing its footprint on the island.
21-Nov-2013 - Aptar Pharma has launched a new auto-injector technology as part of a strategic effort to build its presence in the biopharmaceutical sector.
04-Nov-2013 - Granules India has outlined plans to buy drug intermediate and API maker Auctus Pharma, set up an actives R&D site and announced its intention to wind up its ‘shell’ operation...
31-Oct-2013 - The acquisition of Bend Research by Capsugel may be “a marriage made in heaven” for customers, the firms say, as the first drug delivery tech is transferred.
23-Oct-2013 - Catalent has announced two new softgel solutions as it adds greater versatility to its Advanced Technologies Business Unit.
15-Oct-2013 - AstraZeneca has become the latest company to invest in antibody-drug conjugate (ADC) technology with the acquisition of Spirogen for $200m (€148m).
09-Oct-2013 - Merck says it is shutting two New Jersey facilities as it moves its headquarters to the Kenilworth site where manufacturing ended last week.
05-Sep-2013 - Capsugel will buy Bend Research to expand its dosage form solutions (DFS) business in a deal announced earlier today.
05-Sep-2013 - GlaxoSmithKline is in talks with a number of companies interested in buying its Romanian manufacturing facility that was recently earmarked for closure.
02-Sep-2013 - Novartis-owned Chiron and Panacea Biotec have amicably dissolved their vaccine joint venture due to strategic regions, according to Novartis.